<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B793FDFB-65BB-46A1-80FE-5AB7B2A3CE98"><gtr:id>B793FDFB-65BB-46A1-80FE-5AB7B2A3CE98</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Ferraro</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6665"><gtr:id>0E792377-A0CC-42CF-B760-48E3CE044041</gtr:id><gtr:title>Probing the unexpected sensitivity of autoantibody production to anti-B cell therapy with Rituximab anti-CD20 antibody</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6665</gtr:grantReference><gtr:abstractText>Autoimmune diseases are those in which the body?s immune system attacks itself. In one type, Small vessel Vasculitis (SvV), inflammation occurs within the blood vessels of many different organs within the body, causing widespread damage that may result in bleeding into the lungs and kidney failure.

B cells are part of the immune system, and make antibodies that usually protect the body against infections. In some autoimmune diseases, including SvV, certain antibodies appear to be involved in the process of self-attack. Rituximab, a selective treatment that reduces B cell numbers seems to be effective in treating some of these diseases (including SvV), whilst also reducing the associated antibody levels. In contrast, established antibodies to foreign proteins (e.g. such as those produced by vaccination against tetanus) are not affected by the treatment. This is surprising as both types of antibody were previously thought to be produced by similar mechanisms, and so should be similarly sensitive to Rituximab. Detailed studies will clarify which type of cell produces the autoantibodies in humans, and this will be combined with additional information from studies of mice. This will enhance our fundamental knowledge of how these diseases develop, and may improve our ability to treat them.</gtr:abstractText><gtr:technicalSummary>The B cell depleting agent, Rituximab - a chimeric monoclonal anti-CD20 - shows therapeutic efficacy in Small vessel Vasculitis (SvV), and a range of other diseases with associated autoantibodies. In each disease the therapeutic benefit appears to be associated with observed reductions in the corresponding autoantibody levels, although it is possible that loss of cognate B cell interaction with CD4 T cells plays a role in the clinical benefit. SvV is closely associated with anti-neutrophil cytoplasmic antibodies (ANCA) and ANCA titres often reflect disease activity, with animal models pointing to ANCA?s intrinsic pathogenicity. 
Typically ANCA are IgG with variable (V) region sequences suggesting prior affinity maturation through somatic hypermutation and selection. Experimental studies of affinity maturation of antibody responses do not comfortably explain why ANCA production is Rituximab sensitive. This is because affinity maturation normally appears to occur in germinal centres, which give rise to long-lived plasma cells that do not express the target for Rituximab - CD20. Supporting this is the Rituximab resistance of plasma cells producing affinity-matured neutralizing IgG against bacterial exotoxins. Consequently it is surprising to Immunologists that Rituximab rapidly depletes autoantibody levels. This differential sensitivity of plasma cells to Rituximab suggests a poorly understood mechanism for autoantibody production. The background to the project points to recent evidence that suggests mechanisms for ANCA production that might be Rituximab sensitive and the plan is to probe if one of these is the pathway producing ANCA and other affinity-matured autoantibodies. Investigations will be performed to examine whether ANCA are produced either (a) by atypical antibody-secreting cells that are Rituximab-sensitive through CD20-expression, or (b) by short-lived CD20-ve plasma cells that are frequently renewed from a pool of proliferating Rituximab-sensitive B cls. These findings will be compared with those obtained by studying a mouse model of persistent antibody production, where short-lived plasma cells are replaced by self-renewing clones of B cells. The conclusions should assist understanding of the pathogenesis of SvV and may point to improved treatment of SvV and other autoimmune diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-11</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>181740</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life and Environmental Sciences</gtr:department><gtr:description>Sports Science Research at Birmingham University</gtr:description><gtr:id>4901ECB5-694C-4A94-8709-5D03E14CFE00</gtr:id><gtr:impact>2 Publications:
Gallagher S, Phillips AC, Ferraro AJ, Drayson MT, Carroll D. Social support is positively associated with the immunoglobulin M response to vaccination with pneumococcal polysaccharides. Biological Psychology 2008:78(2);211-215.
Gallagher S, Phillips AC, Ferraro AJ, Drayson MT, Carroll D. Psychosocial factors are associated with the antibody response to both thymus-dependent and thymus-independent vaccines. Brain, Behaviour, and Immunity 2008:22(4);456-460.</gtr:impact><gtr:outcomeId>GtRZ9UT9kn2-1</gtr:outcomeId><gtr:piContribution>Shared expertised in using newly developed technology (antibody assays)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Medical education</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6BA7C556-4988-41D9-8D6F-447751310190</gtr:id><gtr:impact>Various talks within the NHS. Research material included in presentations at local meetings - up to 50 in the audience per time

Greater understanding of the use of Rituximab and the scientific value of observing outcomes of clinical practice</gtr:impact><gtr:outcomeId>jCLMEr5KCVi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical practice</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EA18A2AF-DFBF-4A68-B376-CF003FEB1A7A</gtr:id><gtr:impact>Conversations occuring during subsequent clinical visits by patients who had contributed samples for research work

Virtually all patients are please to hear that research activity occured with their samples. That attitude contributes to the excellent research recruitment in that clinic.</gtr:impact><gtr:outcomeId>1E1FADC56A1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Amgen / Renal Association Conference Bursary</gtr:description><gtr:end>2008-05-02</gtr:end><gtr:fundingOrg>Amgen Inc</gtr:fundingOrg><gtr:id>5D50761D-FF3C-4CAC-95F0-01FC1F32C54C</gtr:id><gtr:outcomeId>Vq38UJaaU3E0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Amgen / Renal Association Conference Bursary</gtr:description><gtr:end>2007-05-02</gtr:end><gtr:fundingOrg>Amgen Inc</gtr:fundingOrg><gtr:id>96B11C17-A4ED-418F-8E4C-6FB4584FC47F</gtr:id><gtr:outcomeId>XcvKrhcEqdo0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Multicentre survey on Rituximab use cited in two clinical reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0BD37811-D7E3-4FCE-92FA-1414C4C7CDA0</gtr:id><gtr:impact>Rituximab has rapidly become a major therapeutic option for the treatment of ANCA-associated vasculitis. This development was occuring, in part, due to the collaborative publication referred to above - and before subsequent multicentre trials were published.</gtr:impact><gtr:outcomeId>bd5L4vQA9Qe</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>After help from a research group in London, I established - for Birmingham University - the technologies to reliably create, validate, and perform multiple customized antibody assays in parallel, using Luminex microsphere-based assays. E.g. 7-plex anti-pneumococcal capsular polysaccharide assays</gtr:description><gtr:id>B4ABF1E5-BBE0-4DB7-95A5-B0E5EB580DE1</gtr:id><gtr:impact>The assays developed - or equivalent assays using the same approach - have now been used by several groups in Birmingham Univeristy. This has resulted in collaborative publications. The protocols for development and use of customized assays have been handed over to the Clinical Immunology service in Birmingham University. They have now been refined and adopted for use in clinical practice.</gtr:impact><gtr:outcomeId>E63F0698FDA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Luminex assays</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3DCBAD30-6FA2-4CDF-80FA-19AB61B25227</gtr:id><gtr:title>Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4eaa54ac5dd86e3b09eae12698bc4e"><gtr:id>cb4eaa54ac5dd86e3b09eae12698bc4e</gtr:id><gtr:otherNames>Ferraro AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5342EA23467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54D08AE1-A32B-4F39-8AA4-29C7D79D04FA</gtr:id><gtr:title>Social support is positively associated with the immunoglobulin M response to vaccination with pneumococcal polysaccharides.</gtr:title><gtr:parentPublicationTitle>Biological psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1b401af8e003acf4477e11e4a448406"><gtr:id>b1b401af8e003acf4477e11e4a448406</gtr:id><gtr:otherNames>Gallagher S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-0511</gtr:issn><gtr:outcomeId>4E3C9F533D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB93249-2503-49D0-AA62-9659C2BC27AB</gtr:id><gtr:title>Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assay.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6738c47341b04bc0ddbc8167c70392d6"><gtr:id>6738c47341b04bc0ddbc8167c70392d6</gtr:id><gtr:otherNames>Whitelegg AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>pm_13453_23_22293629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>344B1B02-21F3-4047-9E92-6EF9A9FFEDDA</gtr:id><gtr:title>Psychosocial factors are associated with the antibody response to both thymus-dependent and thymus-independent vaccines.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1b401af8e003acf4477e11e4a448406"><gtr:id>b1b401af8e003acf4477e11e4a448406</gtr:id><gtr:otherNames>Gallagher S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>227B9B757A2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2042C86-F6D9-4072-BAB0-652016F8BE96</gtr:id><gtr:title>Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4eaa54ac5dd86e3b09eae12698bc4e"><gtr:id>cb4eaa54ac5dd86e3b09eae12698bc4e</gtr:id><gtr:otherNames>Ferraro AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>48762AC0696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19CA62A5-864A-4FD8-A85B-B83000A54D80</gtr:id><gtr:title>A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2dcf3986aac3a24f1cb98f3582dd944"><gtr:id>d2dcf3986aac3a24f1cb98f3582dd944</gtr:id><gtr:otherNames>Jones RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>7776B10CEE9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8364C10-E2EC-470B-A316-0E9D451F274D</gtr:id><gtr:title>Pathogenic mechanisms of anti-neutrophil cytoplasm antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4eaa54ac5dd86e3b09eae12698bc4e"><gtr:id>cb4eaa54ac5dd86e3b09eae12698bc4e</gtr:id><gtr:otherNames>Ferraro AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1744-666X</gtr:issn><gtr:outcomeId>oXVU5she75Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB553F58-0CBC-4359-B41B-65AB0A4CEF55</gtr:id><gtr:title>CD8 T cells induce T-bet-dependent migration toward CXCR3 ligands by differentiated B cells produced during responses to alum-protein vaccines.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b14b0373aa1adb274ac1a893a1bc537d"><gtr:id>b14b0373aa1adb274ac1a893a1bc537d</gtr:id><gtr:otherNames>Serre K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13453_23_23065152</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6665</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>